Eli Lilly’s Ebglyss Shows Long-Term Promise for Atopic Dermatitis Treatment

Eli Lilly and Company (LLY) has announced promising long-term results for its atopic dermatitis treatment, Ebglyss (EHB-glihs). The data, presented at the European Academy of Dermatology and Venereology Congress (EADV), showcases the sustained efficacy of Ebglyss in patients with moderate-to-severe atopic dermatitis.

The ADjoin long-term extension study, which followed patients for up to three years, demonstrated that Ebglyss maintained its effectiveness in clearing skin and controlling symptoms. Over 80% of adult and adolescent patients who initially responded to Ebglyss treatment in the ADvocate 1 and 2 monotherapy trials experienced sustained skin clearance with monthly maintenance dosing.

Specifically, at the three-year mark:

*

84%

of patients taking Ebglyss once monthly and

83%

taking it every two weeks maintained clear or almost-clear skin (IGA 0,1).
*

87%

of patients taking Ebglyss once monthly and

79%

taking it every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90).
*

83%

of patients taking Ebglyss once monthly and

91%

taking it every two weeks did not require high-potency topical corticosteroids or systemic treatments.

These results are significant for patients with atopic dermatitis, a chronic inflammatory skin condition that can cause significant discomfort and impact quality of life. The long-term effectiveness of Ebglyss suggests that it could provide a valuable treatment option for many patients.

The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older. It has also been approved in the European Union and Japan, with additional global markets expected to follow.

Eli Lilly holds exclusive rights for the development and commercialization of Ebglyss in the United States and other regions outside Europe. In Europe, Lilly’s partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.

Eli Lilly stock was up 0.17% at $926 during the premarket session on Wednesday.

This news comes as a positive development for Eli Lilly, particularly in light of the recent approval of its Donanemab treatment for early-stage Alzheimer’s disease in Japan. These successes solidify Eli Lilly’s position as a leader in the pharmaceutical industry.